Micropulse laser for managing DME
Despite the evidence demonstrating its efficacy and safety, subthreshold micropulse laser has faced several obstacles to adoption.
Cheryl Guttman Krader
Published: Monday, March 13, 2017
Retina specialists who perform subthreshold micropulse laser treatment may feel as if they are performing ‘retinal homeopathy'IMPEDIMENTS TO GREATER USE Dr. Gerardo suggested that despite the evidence demonstrating its efficacy and safety, subthreshold micropulse laser has faced several obstacles to adoption. First, laser in general is considered less effective than anti-VEGF therapy, and subthreshold micropulse laser treatment is a latecomer to the treatment armamentarium compared with anti-VEGF injections. In addition, the fact that the subthreshold micropulse modality does not produce visible lesions may create skepticism about whether the treatment is really doing anything. “Retina specialists who perform subthreshold micropulse laser treatment may feel as if they are performing ‘retinal homeopathy’,” Dr. Garcia said. Although we do not have a lot of tools to prove it, findings from imaging with scanning laser opthalmoscopy and spectral domain optical coherence tomography provide evidence that subthreshold micropulse laser does cause a biologic effect. (AM J Opthalmolol 2010:150:856-862) The absence of visible lesions with subthreshold micropulse laser treatment also made it difficult to track treated areas using lasers delivering single spots. This issue, however, has been addressed by the introduction of pattern laser delivery systems that provide better spot coverage without overlap while also increasing treatment efficiency.
Latest Articles
From Lab to Life: Corneal Repair Goes Cellular
Long-awaited cellular therapies for corneal endothelial disease enter the clinic.
Balancing Innovation and Safety
Ensuring access to advanced cell therapies amid regulatory overhaul.
With Eyes on Its Future, ESCRS Celebrates Its Past
Winter Meeting offers opportunities to experiment with new concepts and formats.
Best of ESCRS Winter Meeting 2024
Following the New Generation
EDOF IOLs an option for eyes with mild comorbidities, showing potential in mini-monovision strategies.
Refocus on Multifocals
Trifocal IOLs continue to improve as consensus grows regarding indications and contraindications.
Common Myths in Presbyopia Correction
Patient education key to satisfaction with refractive IOLs.
Reversible Multifocality
Two-lens combination offers low-risk spectacle independence for cataract patients and presbyopes.
Managing a Cataract Surgery Refractive Miss
Weighing the pros and cons of options for intraocular intervention.
Unleashing OCT’s Full Potential
Performance of newest tool for corneal evaluation meets or beats older standard technologies.